# Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

> **NCT00003490** · PHASE2 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** cyclophosphamide
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00003490
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-10
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003490, "Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*